drugset
drugset / Trial / NCT07257055

Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

NCT07257055 ↗

Phase 2 Recruiting 30 enrolled M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.

Timeline

Start
2026-04-01
Primary completion
2028-11-24
Completion
2030-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule — Oral
Subject Glofitamab Monoclonal antibody — Intravenous
Subject Rituximab Monoclonal antibody — Intravenous

Indications

No indication recorded.